July 28, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval
This year nearly 250,000 US women will be diagnosed with Breast Cancer this year and approximately 40,000 women will die. In many cases this is because patients become resistant to drug treatments.
Concarlo is an women-lead biotech oncology company focused on diagnosing and treating cancer by targeting a unique cellular pathway. Their approach harnesses a patient’s own biology to fight cancer. Concarlo has been validated by several publications, an NIH SBIR Phase I award, and a contract with the NIH Nanoparticle Characterization Laboratory.
Concarlo is on a path to begin in-human trials in 1.5 years. In small animal testing, IpY demonstrated greatly increased survivability with tumor regression and no toxicity.
Join our webinar to hear from Concarlo’s CEO and CSO Dr. Stacy Blain and COO LisaMarie Casey as they discuss the science behind a remarkable breakthrough in the treatment of metastatic cancers.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.